Last reviewed · How we verify

Pleural Malignant Effusions — Treatment Landscape & Competitive Intelligence

Pleural Malignant Effusions (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pleural Malignant Effusions, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Blenoxane BLEOMYCIN Bristol-Myers Squibb Cytoprotective Agent Aspartyl/asparaginyl beta-hydroxylase 1973-01-01
Valchlor MECHLORETHAMINE Recordati Alkylating Drug [EPC] 1949-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bristol-Myers Squibb · 1 drug in Pleural Malignant Effusions
  2. Recordati · 1 drug in Pleural Malignant Effusions

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pleural Malignant Effusions:

Cite this brief

Drug Landscape (2026). Pleural Malignant Effusions — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pleural-malignant-effusions. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing